Ulcerative Colitis

Patients with inflammatory bowel disease who reduced the frequency of Entyvio dosing showed high persistence and low rates of relapse, according to study results.

During the American College of Gastroenterology Annual Meeting, I had the honor of hosting the third Healio Disruptive Innovators Awards. Though this event looked different this year – as do so many of our traditions – we enjoyed naming our 2020 Healio Disruptive Innovators.

In this exclusive video, Jordan Axelrad, MD, MPH, from NYU Langone Health discusses his study from the American College of Gastroenterology Virtual Annual Scientific Meeting on the impact of baseline endoscopic and histologic activity on inflammatory bowel disease-related hospitalization.

Patients who have experienced gastrointestinal symptoms before the onset of depression were at increased risk for an eventual diagnosis of inflammatory bowel disease, according to research published in Gut.

A majority of patients with ulcerative colitis treated with Xeljanz achieved clinical response after 8 or 16 weeks induction, according to study results.

Ustekinumab safely maintained a long-term clinical response and remission in patients with Crohn’s disease and ulcerative colitis, according to a presentation at the American College of Gastroenterology Virtual Annual Scientific Meeting.

This award goes to a patient advocate or advocacy group that moved the needle on a disease regarding discussion in the public sphere, better communication between patients and providers and/or advocacy for legislative or regulatory action.

In an exclusive video, Rahul S. Dalal, MD, from Brigham & Women's Hospital in Boston, spoke about predictors of Stelara failure after dose intensification in patients with Crohn’s disease at the American College of Gastroenterology Annual Meeting.

In this exclusive video from the American College of Gastroenterology Virtual Annual Scientific Meeting, Laurie Keefer, PhD, from the Icahn School of Medicine at Mount Sinai discusses her presentation on the GRITT method, a resilience-based care model for patients with inflammatory bowel disease.

“I'm doing fine.” “I'm managing.” “I'm doing okay.”